Forbes is on to my story, of this morning, now. . . .

I posted on it this morning; this afternoon, Forbes is on it:

It seems Merck may have some ulterior motives, here -- Merck gets all of the profits from Cordaptive (due to be approved by FDA as early as next week), which will likely cannibalize some (more) of the Vytorin/Zetia market-share. . . .

In short, "Why share with Schering-Plough (on Vytorin/Zetia), when we have a new drug -- Cordaptive -- one that goes 100 percent to our own bottom line?"

That seems to be what Merck was wondering, softly, yesterday, and now aloud, to Forbes (off the record, of course).